Manufacture

The path to market for a biosimilar involves an abbreviated approval process, focused on proving “biosimilarity”.

We must find ways to better help vaccine manufacturers to fight the flu – and this is why we developed a new challenge agent for H3N2.

As we meet increasing demand and satisfy trends towards self-administration in the injectables market, patient safety must remain the primary driver for innovation.

The challenge of convincing senior staff to invest in continuous bioprocessing.

A generic and inexpensive way to seperate chiral molecules: magnets

Could artificial intelligence help repurpose old drugs for suffers of the degenerative disorder?

The cell therapy industry faces a number of complex problems. Fortunately, they’re good problems to have.

Sitting Down With Cyrus Krakaria, President of Biotechnology for Lupin Limited, Biotech Division, India.

New solutions are needed to teach the immune system to recognize biological drugs as partners rather than plunderers.